Literature DB >> 25232208

Aberrant DNA methyltransferase 1 expression in clear cell renal cell carcinoma development and progression.

Ming Li1, Ying Wang1, Yongsheng Song1, Renge Bu1, Bo Yin1, Xiang Fei1, Qizhen Guo1, Bin Wu1.   

Abstract

OBJECTIVE: To better understand the contribution of dysregulated DNA methyltransferase 1 (DNMT1) expression to the progression and biology of clear cell renal cell carcinoma (ccRCC).
METHODS: We examined the differences in the expression of DNMT1 in 89 ccRCC and 22 normal tissue samples by immunohistochemistry. In addition, changes in cell viability, apoptosis, colony formation and invading ability of ccRCC cell lines (786-0 and Caki-1) were assessed after transfection with DNMT1 siRNA.
RESULTS: We found DNMT1 protein was significantly higher expressed in ccRCC than that of in no-tumor tissues (56.2% and 27.3%, respectively, P=0.018). The expression of DNMT1 was strongly associated with ccRCC tumor size, tumor pathology stage, histological grading, lymph node metastasis, vascular invasion, recurrence and prognosis. Moreover, knockdown of DNMT1 expression significantly inhibited ccRCC cell viability, induced apoptosis, decreased colony formation and invading ability.
CONCLUSIONS: Expression of DNMT1 protein is increased in ccRCC tissues, and DNMT1 expression is associated with poor prognosis of patients. Experiments in vitro further showed DNMT1 played an essential role in proliferation and invasion of renal cancer cells. Moreover, targeting this enzyme could be a promising strategy for treating ccRCC, as evidenced by inhibited cell viability, increased apoptosis, decreased colony formation and invading ability.

Entities:  

Keywords:  Clear cell renal cell carcinoma (ccRCC); DNA methyltransferase 1 (DNMT1); immunohistochemistry; siRNA

Year:  2014        PMID: 25232208      PMCID: PMC4153934          DOI: 10.3978/j.issn.1000-9604.2014.08.03

Source DB:  PubMed          Journal:  Chin J Cancer Res        ISSN: 1000-9604            Impact factor:   5.087


  52 in total

1.  Down-regulated microRNA-152 induces aberrant DNA methylation in hepatitis B virus-related hepatocellular carcinoma by targeting DNA methyltransferase 1.

Authors:  Jinfeng Huang; Yue Wang; Yingjun Guo; Shuhan Sun
Journal:  Hepatology       Date:  2010-07       Impact factor: 17.425

2.  Aberrant epigenetic silencing of tumor suppressor genes is reversed by direct reprogramming.

Authors:  Shulamit Ron-Bigger; Ori Bar-Nur; Sara Isaac; Michael Bocker; Frank Lyko; Amir Eden
Journal:  Stem Cells       Date:  2010-08       Impact factor: 6.277

3.  Increased DNA methyltransferase 1 (DNMT1) protein expression in precancerous conditions and ductal carcinomas of the pancreas.

Authors:  Dun-Fa Peng; Yae Kanai; Morio Sawada; Saori Ushijima; Nobuyoshi Hiraoka; Tomoo Kosuge; Setsuo Hirohashi
Journal:  Cancer Sci       Date:  2005-07       Impact factor: 6.716

4.  Increased levels of DNA methyltransferases are associated with the tumorigenic capacity of prostate cancer cells.

Authors:  Giovanni Luca Gravina; Guido Ranieri; Paola Muzi; Francesco Marampon; Andrea Mancini; Boris Di Pasquale; Luigi Di Clemente; Vincenza Dolo; Anna Maria D'Alessandro; Claudio Festuccia
Journal:  Oncol Rep       Date:  2012-12-18       Impact factor: 3.906

5.  Continuous and low-energy 125I seed irradiation changes DNA methyltransferases expression patterns and inhibits pancreatic cancer tumor growth.

Authors:  Jian-xia Ma; Zhen-dong Jin; Pei-ren Si; Yan Liu; Zheng Lu; Hong-yu Wu; Xue Pan; Luo-wei Wang; Yan-fang Gong; Jun Gao; Li Zhao-shen
Journal:  J Exp Clin Cancer Res       Date:  2011-04-02

6.  TGF-β regulates DNA methyltransferase expression in prostate cancer, correlates with aggressive capabilities, and predicts disease recurrence.

Authors:  Qiang Zhang; Lin Chen; Brian T Helfand; Thomas L Jang; Vidit Sharma; James Kozlowski; Timothy Michael Kuzel; Lihua J Zhu; Ximing J Yang; Borko Javonovic; Yinglu Guo; Scott Lonning; Jay Harper; Beverly A Teicher; Charles Brendler; Nengwang Yu; William J Catalona; Chung Lee
Journal:  PLoS One       Date:  2011-09-30       Impact factor: 3.240

7.  Expression of DNMT1 and DNMT3a are regulated by GLI1 in human pancreatic cancer.

Authors:  ShanShan He; Feng Wang; LiJuan Yang; ChuanYong Guo; Rong Wan; AiWu Ke; Ling Xu; GuoYong Hu; XuanFu Xu; Jie Shen; XingPeng Wang
Journal:  PLoS One       Date:  2011-11-14       Impact factor: 3.240

8.  Downregulation of SAV1 plays a role in pathogenesis of high-grade clear cell renal cell carcinoma.

Authors:  Keiko Matsuura; Chisato Nakada; Mizuho Mashio; Takahiro Narimatsu; Taichiro Yoshimoto; Masato Tanigawa; Yoshiyuki Tsukamoto; Naoki Hijiya; Ichiro Takeuchi; Takeo Nomura; Fuminori Sato; Hiromitsu Mimata; Masao Seto; Masatsugu Moriyama
Journal:  BMC Cancer       Date:  2011-12-20       Impact factor: 4.430

9.  DNA methylation-mediated down-regulation of DNA methyltransferase-1 (DNMT1) is coincident with, but not essential for, global hypomethylation in human placenta.

Authors:  Boris Novakovic; Nick C Wong; Mandy Sibson; Hong-Kiat Ng; Ruth Morley; Ursula Manuelpillai; Thomas Down; Vardhman K Rakyan; Stephan Beck; Stefan Hiendleder; Claire T Roberts; Jeffrey M Craig; Richard Saffery
Journal:  J Biol Chem       Date:  2010-01-13       Impact factor: 5.157

10.  Expression of methylation-related genes is associated with overall survival in patients with non-small cell lung cancer.

Authors:  J Xing; D J Stewart; J Gu; C Lu; M R Spitz; X Wu
Journal:  Br J Cancer       Date:  2008-04-15       Impact factor: 7.640

View more
  9 in total

1.  Incorporating DNA Methyltransferase Inhibitors (DNMTis) in the Treatment of Genitourinary Malignancies: A Systematic Review.

Authors:  Michal Chovanec; Fadi Taza; Maitri Kalra; Noah Hahn; Kenneth P Nephew; Michael J Spinella; Costantine Albany
Journal:  Target Oncol       Date:  2018-02       Impact factor: 4.493

2.  Interplay of DNA methyltransferase 1 and EZH2 through inactivation of Stat3 contributes to β-elemene-inhibited growth of nasopharyngeal carcinoma cells.

Authors:  JingJing Wu; Qing Tang; LiJuan Yang; YuQing Chen; Fang Zheng; Swei Sunny Hann
Journal:  Sci Rep       Date:  2017-03-30       Impact factor: 4.379

3.  Link between dysregulated hypoxia signaling and aberrant methylation in clear cell renal cell carcinoma?

Authors:  Niraj Shenoy
Journal:  Chin J Cancer Res       Date:  2017-04       Impact factor: 5.087

4.  Sohlh2 Inhibits the Malignant Progression of Renal Cell Carcinoma by Upregulating Klotho via DNMT3a.

Authors:  Yang Liu; Weiwei Cui; Ruihong Zhang; Sujuan Zhi; Lanlan Liu; Xuyue Liu; Xiaoning Feng; Yanru Chen; Xiaoli Zhang; Jing Hao
Journal:  Front Oncol       Date:  2022-01-19       Impact factor: 6.244

5.  High DNMT1 Expression in Stromal Fibroblasts Promotes Angiogenesis and Unfavorable Outcome in Locally Advanced Breast Cancer Patients.

Authors:  Layla A Al-Kharashi; Asma Tulbah; Maria Arafah; Abdelmonneim M Eldali; Taher Al-Tweigeri; Abdelilah Aboussekhra
Journal:  Front Oncol       Date:  2022-06-02       Impact factor: 5.738

6.  Differential expression of the epigenetic methylation-related protein DNMT1 by breast cancer molecular subtype and stromal histology.

Authors:  Eunah Shin; YuKyung Lee; Ja Seung Koo
Journal:  J Transl Med       Date:  2016-04-12       Impact factor: 5.531

7.  The network of DAB2IP-miR-138 in regulating drug resistance of renal cell carcinoma associated with stem-like phenotypes.

Authors:  Eun-Jin Yun; Jer-Tsong Hsieh; Jiancheng Zhou; Chun-Jung Lin; Shan Xu; John Santoyo; Elizabeth Hernandez; Chih-Ho Lai; Ho Lin; Dalin He
Journal:  Oncotarget       Date:  2017-05-09

8.  Oxidative stress-induced epigenetic changes associated with malignant transformation of human kidney epithelial cells.

Authors:  Prathap Kumar S Mahalingaiah; Logeswari Ponnusamy; Kamaleshwar P Singh
Journal:  Oncotarget       Date:  2017-02-14

9.  Targeting EP4 downstream c-Jun through ERK1/2-mediated reduction of DNMT1 reveals novel mechanism of solamargine-inhibited growth of lung cancer cells.

Authors:  Yuqing Chen; Qing Tang; Qian Xiao; LiJun Yang; Swei S Hann
Journal:  J Cell Mol Med       Date:  2016-09-13       Impact factor: 5.310

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.